SCHEMBL2115019

SCHEMBL2115019

COCCN(CCOC)c1nc(N(CCOC)CCOC)nc(N(CCOC)CCOC)n1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 2/20 0.53
CRHR1 P34998 7/20 0.46
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 1/20 0.39
CTH P32929 1/20 0.38
CDC7 O00311 1/20 0.37
CYP3A4 P08684 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
DYRK1A Q13627 1/20 0.35
PIK3CD O00329 2/20 0.34
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
CCNE2 O96020 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6961020 0.89 SLC29A1 (0.46) SLC29A1CRHR1SMN1; SMN2MAPTCTH
SCHEMBL12994846 0.86 SLC29A1 (0.44) SLC29A1CRHR1SMN1; SMN2MAPTCTH
SCHEMBL16284291 0.77 CRHR1 (0.49) SLC29A1CRHR1SMN1; SMN2MAPTCYP3A4
SCHEMBL10377680 0.75 SLC29A1 (0.40) SLC29A1CRHR1CTHCDC7MEN1
SCHEMBL8108845 0.75 SLC29A1 (0.39) SLC29A1CRHR1SMN1; SMN2CTHCDC7
SCHEMBL14029791 0.74 DYRK1A (0.44) SLC29A1CRHR1SMN1; SMN2CDC7DYRK1A
SCHEMBL123963 0.72 ALDH1A1 (0.38) SLC29A1CRHR1SMN1; SMN2MAPTLMNA
SCHEMBL26134280 0.72 ALDH1A1 (0.38) SLC29A1CRHR1SMN1; SMN2MAPTLMNA
SCHEMBL7469761 0.72 SLC29A1 (0.37) SLC29A1CRHR1SMN1; SMN2CTHCDC7
SCHEMBL22022706 0.72 HTT (0.33) SLC29A1CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142446-A1 ACIDIC AQUEOUS COMPOSITION FOR ELECTROLYTICALLY DEPOSITING A COPPER DEPOSIT Atotech Deutschland GmbH & Co. KG (DE) 2023-05-11 US disclosed
US-20200326623-A1 A NEGATIVE TONE LIFT OFF RESIST COMPOSITION COMPRISING AN ALKALI SOLUBLE RESIN AND CROSS LINKERS AND A METHOD FOR MANUFACTURING METAL FILM PATTERNS ON A SUBSTRATE MERCK PATENT GMBH (DE) 2020-10-15 US disclosed
US-8158308-B2 Including heterocyclic monofunctional thiol compound; storage stability; developability at high sensitivity; formation of fine rectangular pattern at low binder levels FUJIFILM CORPORATION (JP) 2012-04-17 US disclosed
US-20080226994-A1 NEGATIVE CURABLE COMPOSITION, COLOR FILTER, AND METHOD OF PRODUCING THE SAME FUJIFILM CORPORATION (JP) 2008-09-18 US disclosed
EP-1970759-A1 Negative curable composition, color filter, and method of producing the same Fujifilm Corporation (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142446-A1 ACIDIC AQUEOUS COMPOSITION FOR ELECTROLYTICALLY DEPOSITING A COPPER DEPOSIT PCNA, WASHC5, POLR1C SLC29A1 3345/4885CRHR1 3383/4885SMN1; SMN2 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.